@WHO: Sotrovimab is a monoclonal antibody drug. Studies are ongoing but early laboratory studies indicate that it continues to work against the #COVID19 Omicron variant https://t.co/UAc21Wgxbl https://t.co/7bkJK5bR4g

http://twitter.com/WHO
via IFTTT